gsk201507206k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending July 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--


GlaxoSmithKline plc
                     
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 20 July 2015, of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR'), following increases in their notional interests in Ordinary Shares and American Depositary Shares (ADSs), at a price of 1350.50 pence per Ordinary Share and $41.36 per ADS, following the re-investment of dividends paid on Ordinary Shares and ADSs held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
 
 
 
Director/PDMR
 
Number of Ordinary Shares acquired under the personal contribution element of the plan
 
Number of Ordinary Shares acquired under the matching element of the plan
(GSK contribution)
 
Sir Andrew Witty
 
1780
 
1780
 
Mr S Dingemans
 
679
 
679
 
Mr R G Connor
 
353
 
353
 
Mr N Hirons
 
76
 
76
 
Mr S A Hussain
 
304
 
304
 
Mr D S Redfern
 
379
 
379
 
Ms C Thomas 
 
260
 
260
 
Mr P C Thomson
 
127
 
127
 
Dr P J T Vallance
 
910
 
910
 
Ms E Walmsley
 
537
 
537
 
 
 
Director/PDMR
 
Number of ADSs acquired under the personal contribution element of the plan
 
Number of ADSs acquired  under the matching element of the plan
(GSK contribution)
 
Dr M M Slaoui
 
694
 
694
 
Mr W C Louv
 
178
 
178
 
Mr D E Troy
 
292
 
292
 
V A Whyte
Company Secretary
 
20 July 2015

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: July 20, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc